Drug Profile
Ad26 EBOV vaccine - Crucell/NIH
Alternative Names: Ad26 EBOV vaccine - NIH/Crucell; Ad26-ZEBOV - Crucell/NIH; Ad26-ZEBOV - NIH/Crucell; Ad26.ZEBOV; Ad26.ZEBOV - NIH/Crucell; Ebola virus vaccine - Crucell/NIH; Ebola virus vaccine - NIH/Crucell; VAC-52150; ZabdenoLatest Information Update: 29 Dec 2023
Price :
$50
*
At a glance
- Originator Crucell; National Institutes of Health (USA)
- Developer Bavarian Nordic; Crucell; Janssen; London School of Hygiene & Tropical Medicine; National Institute of Allergy and Infectious Diseases
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Ebola virus infections
Most Recent Events
- 13 Dec 2023 Janssen terminates a phase III trial for Ebola virus infections (In adolescents, In children, In the elderly, Prevention, In adults, In infants, In neonates) in USA, Burkina Faso, France, Kenya, Tanzania, Uganda, and the UK due to the pandemic with only one participant in follow up, as the impact on the safety was determined to be negligible (NCT02661464)
- 02 Mar 2023 Janssen completes phase-III clinical trial in Ebola virus infections (Prevention, In adults, In the elderly) in Rwanda (IM) (NCT04556526)
- 02 Dec 2022 No development reported - Phase-II for Ebola virus infections (In adolescents, In children, In the elderly, Prevention, In adults) in Uganda (IM)